Promoting research partnerships 

to improve veterans’ health

NAVREF News Center

  • 19 Mar 2019 2:33 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $100 million (M) to the Department of Defense Prostate Cancer Research Program (PCRP)to support innovative, high-impact prostate cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program Research, Development, Test, and Evaluation appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The PCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the Government.

    The mission of the PCRP is to fund research that will lead to the elimination of death from prostate cancer and enhance the well-being of Service members, Veterans, and all the men and their families who are experiencing the impact of the disease.  Applications submitted to the FY19 PCRP must address one or more of the program’s Overarching Challenges:

    ·         Improve the quality of life for survivors of prostate cancer

    ·         Develop treatments that improve outcomes for men with lethal prostate cancer

    ·         Reduce lethal prostate cancer in African Americans, Veterans, and other high-risk populations

    ·         Define the biology of lethal prostate cancer to reduce death

     

    https://cdmrp.army.mil/pubs/press/2019/19pcrppreann

     

    Early Investigator Research Award

    By March 31, 2020, Postdoctoral Principal Investigators (PIs):

    ·         Must possess a doctoral degree (or equivalent)

    ·         Have 3 years or less of postdoctoral research experience (excluding clinical residency or clinical fellowship training)

    ·         Supports research opportunities focused on prostate cancer for individuals in the early stages of their careers.

    ·         PIs must have a designated mentor who is an experienced prostate cancer researcher.

    ·         Maximum funding of $200,000 for direct costs (plus indirect costs).

    ·         Maximum period of performance is years.

     

    Physician Research Award

    At the time of application submission, the PI must be either:

    ·      In the last year of an accredited medical residency or medical fellowship program

    ·      or

    ·      Within 5 years of having initiated a faculty appointment (including Instructor positions)

    ·      Supports a mentored research experience to prepare physicians with clinical duties for careers in prostate cancer research.

    ·      PIs must demonstrate a commitment to a career at the forefront of prostate cancer research and clinical practice.

    ·      PIs must have a designated mentor with an established research program in prostate cancer.

    ·     Maximum funding of $750K for direct costs (plus indirect costs).

    ·      Maximum period of performance is 4 years.

     

    Idea Development Award

    Established Investigators:  Independent investigators at all levels

    Or

    New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    ·      Have the freedom to pursue individual aims without formal mentorship

    ·      Have not previously received a PCRP Idea Development Award and/or Health Disparity Research Award

    ·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)

    ·      Preproposal is required; application submission is by invitation only.

    ·      Supports new ideas that represent innovative, high-risk/high-gain approaches to prostate cancer research and have the potential to make an important contribution to one or more of the FY19 PCRP Overarching Challenges.

    ·      Emphasis is equally placed on Innovation and Impact.

    ·      Preliminary data are encouraged, but not required.

    ·      Clinical trials are not allowed.

    ·      Each PI may submit only one application.

    ·      New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers

    ·      Established Investigators:

    ·      Maximum funding of $750,000 for direct costs (plus indirect costs).

    ·      New Investigators:

    ·      Maximum funding of $600,000 for direct costs (plus indirect costs)

    ·      Maximum period of performance is 3 years.

     

    Health Disparity Research Award

    Established Investigators:  Independent investigators at all levels

    or

    New Investigators:  Investigators that meet the following criteria at the application submission deadline date:

    ·      Have the freedom to pursue individual aims without formal mentorship

    ·      Have not previously received a PCRP Health Disparity Research Award and/or Idea Development Award

    ·      Have either completed at least 3 years of postdoctoral training or fellowship or are within 10 years after completion of terminal degree (excluding residency or family leave)

    ·      Supports new ideas for prostate cancer research that have the potential to make an important contribution to reducing and ultimately eliminating disparities in prostate cancer incidence, morbidity, and mortality. 

    ·      Primary emphasis will be placed on the potential impact of the proposed work.

    ·      Preliminary data are encouraged, but not required.

    ·      Proposed projects may include basic, translational, population science, or clinical research, including clinical trials.

    ·      New Investigator Option supports applicants early in their faculty appointments or in the process of developing independent research careers.

    ·      Established Investigators:

    ·      Maximum funding of $750,000 for direct costs (plus indirect costs).

    ·      New Investigators:

    ·      Maximum funding of $600,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 3 years.

     

    Translational Science Award

    ·      Independent investigators at all levels

    ·      Supports translational studies that will advance promising ideas into clinical applications.

    ·      The potential impact of the research is expected to be significant and go beyond an incremental advance.

    ·      Preliminary data to support feasibility are required.

    ·      Proposed projects may include basic, translational, population science or clinical research, but must demonstrate clinical relevance.

    ·      Maximum funding of $750,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is years.

     

    Clinical Trial Award

    ·      Independent investigators at all levels

    ·      Supports hypothesis-based, early-phase clinical trials (e.g., Phase 0, Phase I, pilot Phase II) to test interventions that will have a major impact on one or more of the FY19 PCRP Overarching Challenges.

    ·      Interventions may include drugs, devices, biologics, surgical procedures, behavior modifications, or other types.

    ·      Investigational New Drug or Investigational Device Exemption approvals, if applicable, must be in place by the time of application submission.

    ·      Letter of support to demonstrate proof of possession of sufficient drug supply to conduct study must be provided (if appropriate).

    ·      Clinical trials are expected to be initiated within 12 months of the award date.

    ·      Maximum funding of $2,000,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 4 years.

     

    Synergistic Population and Data Science Award

    ·      Independent investigators with a faculty-level appointment (or equivalent)

    ·      Supports multi-institutional partnerships that will leverage existing prostate cancer patient databases and cohorts to address high-impact questions responsive to the FY19 PCRP Overarching Challenges.

    ·      Allows for development of infrastructure to facilitate the implementation of research ideas across databases, as well as conducting hypothesis-based studies utilizing the multi-institutional databases/cohorts.

    ·      Minimum of three institutions and three patient databases and/or cohorts is required.

    ·      Maximum funding of $1,500,000 for direct costs (plus indirect costs).

    ·      Maximum period of performance is 4 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 19 Mar 2019 9:16 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $16 million (M) to the Department of Defense Parkinson’ Research Program (PRP) to support research to understand, prevent, diagnose, and treat Parkinson’s disease.  Applications to the FY19 PRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The PRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

     

    IMPORTANT:  The PRP seeks to focus applications and direct funding by providing Focus Areas to address the critical needs in Parkinson’s disease research. 

    https://cdmrp.army.mil/pubs/press/2019/19prppreann

    Investigator-Initiated Research Award

    Independent investigators at or above the level of assistant professor (or equivalent)

    • ·        Supports highly rigorous, high-impact research projects that have the potential to make an important contribution to Parkinson’s disease research and/or patient care.
    • ·        Preliminary data to support feasibility are required.  Any unpublished, preliminary data provided should originate from the laboratory of the Principal Investigator (PI) or a member(s) of the research team.

    ·        Preliminary data to support feasibility required

    • ·        Clinical trials not allowed

    Partnering PI Option:

    • ·        Provides a higher level of funding to support synergistic partnerships between two or three independent investigators collaborating on a single application.
    • ·        PIs are expected to demonstrate within the application the synergistic components that will significantly advance the project, such that the research outcomes could not otherwise be accomplished through the independent efforts of a single PI.
    • ·        The proposed partnership should result in a level of productivity that is greater than that achievable by each PI independently. 
    • ·        Applications to this award mechanism must address at least one of the four FY19 Focus Areas noted below:
    • ·        Clinical and research applications of digital health technology for Parkinson’s disease monitoring, including early identification
    • ·        Mechanisms of non-motor symptoms of Parkinson’s disease from basic biology to clinical application
    • ·        Sleep biology in Parkinson’s disease
    • ·        Quantifiable gene-environment interactions and the risk of Parkinson’s disease

    Individual PI:

    ·       Maximum funding of $1.5 million (M) in total costs

    ·       Maximum period of performance years

    Partnering PI Option:

    ·       Maximum funding of $2.4M in total costs

    • ·       Maximum period of performance years

     

    Early Investigator Research Award

    Postdoctoral or clinical fellow, instructor, or assistant professor within 10 years of advanced degree or residency training (or equivalent)

    Verification of eligibility criteria must be provided in an Eligibility Statement signed by an appropriate institutional official and the PI. 

    • ·         The EIRA supports early-career investigators exploring innovative, high-impact ideas or new technologies applicable to Parkinson’s disease research and/or patient care. The PRP seeks applications from investigators working in a broad spectrum of disciplines including, but not limited to, basic science, engineering, bioinformatics, population science, translational research, and clinical research.
    • ·         The application should demonstrate the PI’s potential for, and commitment to, pursuing a career in Parkinson’s disease research under the guidance of a designated Mentor(s). Evaluated criteria will include mentorship and mentorship environment with an identified path to independence.

    ·         Preliminary data not required

    ·         Clinical trials not allowed

    • ·         Applications to this award mechanism must address at least one of the four FY19 Focus Areas.

    ·         Maximum funding of $360,000 in total costs

    • ·         Maximum period of performance 2 years

     

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 19 Mar 2019 9:15 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriations Act provides $15 million (M) to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research.  Applications to the FY19 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 NFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    https://cdmrp.army.mil/funding/nfrp

    Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY19 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY19 NFRP.  If the proposed research project does not address one of the FY19 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

    • ·         Health services research
    •          Evidence-based best clinical practices
    • §  Outcomes of specific therapies, including surgery and radiation therapy
    •          Implementation and access to NF-specific healthcare
    •          Utilization of technology and informatics
    • ·         Heterogeneity of NF-related tumors
    • ·         Non-tumor manifestations
    •          Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations
    • ·         Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
    •          Transition from benign to malignant
    • ·         Nutritional, environmental, and other modifiers of NF
    • ·         Preclinical efficacy studies
    • ·         Target identification, drug discovery
    • ·         Targeted immunotherapies
    •  

    Clinical Trial Award – Letter of Intent due May 23, 2019

    Must be at or above the level of Assistant Professor (or equivalent).

    ·         Supports research with the potential to have a major impact on the treatment or management of neurofibromatosis (NF)

    ·         Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis.  Combinations of phases are permitted.

    ·         Funding must support a clinical trial and may not be used for preclinical studies.

    ·         Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

    ·       Maximum allowable funding for the entire period of performance is $800,000 in direct costs ($1,000,000 for direct costs if requesting the Qualified Collaborator Option).

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    • ·       Maximum period of performance is years

     

    Exploration – Hypothesis Development Award – Letter of Intent due May 23, 2019

    Investigators at all academic levels (or equivalent)

    ·         Supports the initial exploration of innovative, high-risk, high-gain concepts in NF research.

    ·         Preliminary and/or published data encouraged but not required.

    ·         Projects involving human subjects or human anatomical substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·         Clinical trials not allowed.

    ·       The maximum allowable funding for the entire period of performance is of $100,000 in direct costs.

    ·       Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    • ·       Maximum period of performance is 2 years
    •  

    New Investigator Award – Letter of Intent due May 23, 2019

    Must be either:

    An independent investigator at or below the level of Assistant Professor (or equivalent) and must plan to commit at least 30% of his/her effort toward the proposed research project; or

    An established investigator in an area other than NF at or above the level of Assistant Professor seeking to transition into a career in NF research and must plan to commit at least 10% of his/her effort toward the proposed research project.

    To be eligible, applicants may not have received more than $300,000 in direct costs for NF research as a Principal Investigator of one or more Federally funded, non-mentored peer reviewed grants.

    ·       Supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research.

    ·       Prior experience in NF research is not required.

    ·       Preliminary and/or published data relevant to NF and the proposed research project is required.

    ·       Clinical trials not allowed

    ·      The maximum allowable funding for the entire period of performance is $450,000 in direct costs.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·      Maximum period of performance is 3 years

     

    Early Investigator Research Award – Letter of Intent due May 23, 209

    The investigator must:

    Be involved in postdoctoral training or medical residency program; and

    Possess at least 1 and up to 4 years of continuous postdoctoral research experience by the Early Investigator Research Award application submission deadline; and

    Possess a clinical doctoral degree (i.e., Ph.D., M.D. /Ph.D., D.O. /Ph.D.) or a clinical doctoral degree (i.e., M.D. /D.O. or Ph.D. in a clinical discipline) from an accredited organization or program.

    ·      Supports NF-focused research opportunities for individuals in the early stages of their careers.

    ·      Investigators must have a designated mentor who is an experienced NF researcher.

    ·      The maximum allowable funding for the entire period of performance is $200,000 in direct costs.

    ·      Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.

    ·      Maximum period of performance is 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism is also found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk

    301-682-5507
    help@eBrap.org


  • 8 Mar 2019 10:28 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $3 million (M) to the Department of Defense Bone Marrow Failure Research Program (BMFRP)to support scientifically meritorious research focused on BMF diseases.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The BMFRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 BMFRP Program Announcements and General Application Instructions for the following award mechanism are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcement is released.  This pre-announcement should not be construed as an obligation by the government.

    https://cdmrp.army.mil/pubs/press/2019/19bmfrppreann

    Idea Development Award

    Established Investigators: 

    • Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from first faculty appointment or

    Early Career Investigators:

    • Investigators at the level of Assistant Professor (or equivalent) and less than 10 years from first faculty appointment.
    • Preproposal is required; full application submission is by invitation only.
    • Supports innovative ideas and high-impact approaches based on scientifically sound evidence to move toward the vision to understand and cure BMF.
    • Strong BMF research team.
    • May include relevant preliminary data.
    • Clinical trials will not be supported.
    • Maximum funding of $325,000 in direct costs (plus indirect costs)
    • Period of performance not to exceed 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 4 Mar 2019 9:12 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Multiple Sclerosis Research Program (MSRP)to support pioneering concepts and high-impact research that are relevant to the prevention, etiology, pathogenesis, assessment, and treatment of multiple sclerosis (MS) to ultimately lessen its personal and societal impact.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The MSRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 MSRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY19 MSRP must address at least one of the following Focus Areas:

    1. Factors That Promote Central Nervous System Regenerative Potential in Demyelination

    Supports innovative mechanistic studies and translational approaches to promote axonal protection, regeneration, or remyelination in MS and/or relevant experimental models. 

    Note:  Studies addressing the following topics will not be considered for funding: developmental myelination, dysmyelination, blood-brain barrier permeability, basic mechanisms of demyelination, neurodegeneration, or inflammatory mechanisms and anti-inflammatory therapeutic strategies that limit tissue injury secondarily.

    1. Correlates of Disease Activity and Progression in MS

    Supports the identification and/or validation of correlates of disease activity and progression using pre-existing specimens and/or data acquired from well-characterized, adequately controlled, and sufficiently powered patient cohorts.

    Note:  The study must leverage pre-existing specimens and/or data that are available at the time of application submission; collection of a single set of specimens and/or data collected at one additional time point from participants in the existing cohort is allowed.

    1. Biology and Measurement of MS Symptoms

    Supports studies on the biology and measurement of MS symptoms, which may include pain, fatigue, depression, anxiety, loss of bladder control, impaired mobility, and cognitive, motor, visual, or sexual dysfunction. 

    Note:  Studies of disease-modifying or regenerative therapies that secondarily impact MS symptoms will not be considered for funding under this Focus Area.

     

     

     

    Exploration – Hypothesis Development Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·         Pre-application submission is required; application submission is by invitation only.

    ·         Supports the initial exploration of innovative, high-risk, high-gain, and potentially groundbreaking concepts in the MS research field.

    ·         Preliminary data not required.

    • Clinical trials not allowed.

    ·         Maximum funding of $150,000 for direct costs (plus indirect costs)

    • Maximum period of performance is years.
    •  

     

    Investigator-Initiated Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent)

    ·         Pre-application submission is required; application submission is by invitation only.

    ·         Supports highly rigorous, high-impact research with the potential to make an important contribution to MS research and/or patient care.

    ·         Preliminary data required.

    • Clinical trials not allowed.

    ·         Maximum funding of $600,000 for direct costs (plus indirect costs)

    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP home page at https://eBRAP.org.  For more information about the MSRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 25 Feb 2019 1:14 PM | Hawk Tran (Administrator)

    The FY19 Defense Appropriations Act provides $15 million (M) to the Department of Defense Neurofibromatosis Research Program (NFRP) to support innovative, high-impact NF research.  Applications to the FY19 NFRP are being solicited by the U.S. Army Medical Research Acquisition Activity (USAMRAA).  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The NFRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 NFRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Areas of Emphasis: The NFRP encourages applications that specifically address the critical needs of the NF community in one or more of the FY19 Areas of Emphasis.  Not all Areas of Emphasis are applicable to each award mechanism offered by the FY19 NFRP.  If the proposed research project does not address one of the FY19 Areas of Emphasis, justification that the proposed research project addresses an important problem related to NF research and/or patient care should be provided.

    • ·        Health services research
    •        Evidence-based best clinical practices
    • §  Outcomes of specific therapies, including surgery and radiation therapy
    •        Implementation and access to NF-specific healthcare
    •        Utilization of technology and informatics
    • Heterogeneity of NF-related tumors
    • Non-tumor manifestations
    • Cognitive, behavior, sleep, pain, hypotonia, communication, etc., including quality of life measures, and self-reported and underreported manifestations
    • ·        Novel disease and treatment response markers using genomics, epigenetics, systems biology, metabolomics, or similar approaches
    • Transition from benign to malignant
    • ·        Nutritional, environmental, and other modifiers of NF
    • ·        Preclinical efficacy studies
    • ·        Target identification, drug discovery
    • ·        Targeted immunotherapies

    Clinical Trial Award

    Independent investigators at or above the level of Assistant Professor (or equivalent).

    ·        Funds Phase 0, I, or II clinical trials relevant to NF and/or schwannomatosis; combinations of phases are permitted.

    ·        Funding must support a clinical trial and may not be used for preclinical studies.

    ·        Scientific rationale and preliminary data required for Phase I, II clinical trial applications.

    ·      Maximum funding of $800,000 for direct costs (plus indirect costs)

    ·      Maximum funding of $1,000,000 for direct costs (plus indirect costs) for applications including a Collaborator

    • ·      Maximum period of performance is years

    Exploration – Hypothesis Development Award

    All academic levels (or equivalent)

    ·        Funds the initial exploration of innovative, high-risk, high-gain and potentially groundbreaking concepts in NF research.

    ·        Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.104(d) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.

    ·        Preliminary and/or published data is encouraged but not required.

    ·        Clinical trials not allowed.

    ·      Maximum funding of $100,000 for direct costs (plus indirect costs)

    • ·      Maximum period of performance is 2 years

    Investigator-Initiated Research Award

    Independent investigators at or above the level of Assistant Professor (or equivalent) and must plan to commit at least a 10% level of effort for each budget period throughout the entirety of the award.

    ·       Funds highly rigorous, high-impact research projects that have the potential to make an important contribution to NF research and/or patient care.

    ·       Optional Features: Applications meeting criteria identified in the announcement may apply for a higher level of funding for the following options: Qualified Collaborator and/or NF Open Science Initiative (NF-OSI).

    ·       Preliminary and/or published data is required.

    ·       Clinical trials not allowed.

    ·     Maximum funding of $525,000 for direct costs (plus indirect costs)

    ·     Maximum funding of $575,000 for direct costs (plus indirect costs) for applications including either an Optional Qualified Collaborator or NF-OSI option

    ·     Maximum funding of $625,000 for direct costs (plus indirect costs) for applications including both, an Optional Qualified Collaborator and the NF-OSI

    ·     Maximum period of performance is 3 years

    New Investigator Award

    Independent investigators at or below the level of Assistant Professor (or equivalent) or an established investigator at or above the level of Assistant Professor seeking to transition into a career in NF research.

    ·      Supports the continued development of promising independent investigators and/or the transition of established investigators into a career in the field of NF research.

    ·      Experience in NF research is allowed, but not required.

    ·      Preliminary and/or published data is required.

    ·      Clinical trials not allowed

    ·     Maximum funding of $450,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance is 3 years

    Early Investigator Research Award

    Postdoctoral Ph.D. or M.D. PIs:

    ·   Must have successfully defended a doctoral thesis or possess an M.D. degree, and Have at least 3 years and up to 6 years of consecutive postdoctoral fellowship

    ·     Supports research opportunities focused on NF for individuals in the early stages of their careers.

    ·     PIs must have a designated mentor who is an experienced NF researcher.

    ·     Maximum funding of $200,000 for direct costs (plus indirect costs)

    ·     Maximum period of performance is 2 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the NFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 25 Feb 2019 11:51 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $90 million (M) to the U.S. Department of Defense Peer Reviewed Cancer Research Program (PRCRP) to support innovative, high-impact cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency J9, Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The PRCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 PRCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on the Grants.gov website in early April 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Congressionally Directed Topic Areas:  To be considered for funding, applications for the FY19 PRCRP must address at least one of the Topic Areas as directed by Congress.  Research applications in the areas of breast, prostate, lung (excluding mesothelioma), kidney, melanoma, or ovarian cancer will not be accepted.

    The FY19 PRCRP Topic Areas are:

    • ·         Bladder cancer
    • ·         Blood cancers
    • ·         Brain cancer
    • ·         Cancer in children, adolescents, and young adults*
    •  
    • ·         Colorectal cancer
    • ·         Immunotherapy
    • ·         Listeria vaccine for cancer
    • ·         Liver cancer
    • ·         Lymphoma
    • ·         Mesothelioma
    • ·         Neuroblastoma
    • ·         Pancreatic cancer
    • ·         Pediatric brain tumors
    • ·         Rare cancersǂ
    • ·         Stomach cancer
    •  

    *The definition of adolescents and young adults is derived from the National Cancer Institute (https://www.cancer.gov/types/aya) and can be considered to be people between 15 and 39 years of age.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s). Research should be targeted toward children (ages 0-14 years), adolescents (ages 15-24 years), and/or young adults (ages 25-39 years).

    As derived from the National Cancer Institute Dictionary of Cancer terms (http://www.cancer.gov/publications/dictionaries/cancer-terms).  Immunotherapy is a type of biological therapy that uses substances to stimulate or suppress the immune system to help the body fight cancer.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    ǂRare cancer is defined by the National Cancer Institute as a cancer that occurs in fewer than 15 out of 100,000 people each year.  Cancers studied under this Topic Area should be within the scope of the Congressional language and the intent of the Program Announcement(s).

    The FY19 PRCRP Military Relevance Focus Areas are listed below:

    It is central to the vision and mission of the PRCRP that applications address how the proposed research is related to military health and mission readiness of both deployed and non-deployed personnel, their dependents, retirees, and Veterans. The FY19 PRCRP requires all applications to respond to at least one of Military Relevance Focus Areas listed below:

    • Militarily relevant risk factors associated with cancer (e.g., ionizing radiation, chemicals, infectious agents, environmental carcinogens, and stress)
    • Gaps in cancer prevention, early detection/diagnosis, prognosis, treatment, and/or survivorship that may impact mission readiness and the health and well-being of military members, Veterans, their beneficiaries, and the general public

    Career Development Award

    Principal Investigator (PI): Independent early-career investigator within 10 years after completion of his/her terminal degree (excluding time spent in residency or on family medical leave) by the time of the application submission deadline.

    Career Guide: Investigators at or above the level of Associate Professor (or equivalent); must have a proven publication and funding record in cancer research. 

    ·         Letter of Intent is required.  An invitation to submit a full application is not required.

    ·         Supports independent, early-career investigators to conduct impactful research with the mentorship of an experienced cancer researcher.

    ·         Must address at least one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $360,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 3 years.

     

    Horizon Award

    Principal Investigator (PI):

    Predoctoral candidate within 2 years of completion of required coursework/laboratory rotations, successfully passed qualifying examinations, and is working in his/her Mentor’s laboratory application submission deadline.

    Or

    Postdoctoral fellow within 3 years of completion of terminal degree and is working in his/her Mentor’s laboratory at application submission deadline.

    Mentor: Investigators at or above the level of Assistant Professor (or equivalent); must have a proven publication and funding record in cancer research. 

    PI and Mentor must be at the same organization.

    ·         Letter of Intent is required.  An invitation to submit a full application is not required.

    ·         Supports junior-level scientists in conducting impactful research with the mentorship of an experienced cancer researcher (i.e., Mentor).

    ·         Must address at least one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $150,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 2 years.

     

    Idea Award with Special Focus

    Independent investigator with a faculty-level appointment (or equivalent).

    ·         Preproposal is required; application submission is by invitation only.

    ·         Supports innovative, untested, high-risk/potentially high-reward concepts, theories, paradigms, and/or methods in cancer research relevant to Service members, their families, and other military beneficiaries.

    ·         Emphasis on innovation and military relevance/impact.

    ·         Must address at least one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are not required.

    ·         Clinical trials are not allowed.

    ·       Maximum funding for the entire period of performance is $400,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 2 years.

     

    Impact Award

    Independent investigators at or above the level of Assistant Professor (or equivalent) are eligible to submit an application.

    ·         Preproposal is required; application submission is by invitation only.

    ·         Supports hypothesis-driven, high impact research.

    ·         Encourages applications that support research projects or ideas that specifically focus on critical scientific and clinical cancer issues, which, if successfully addressed, have the potential to make a major impact on one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are required.

    ·         Clinical Trials are allowed.

    ·       Maximum funding for the entire period of performance is $1,000,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 3 years.

     

    Translational Team Science Award

    At least two and up to three PIs must partner in one overarching correlative or translational research study.

    At least one of the PIs is encouraged to be a military or US Department of Veterans Affairs investigator.

    ·         Preproposal is required; application submission is by invitation only.

    ·         Emphasizes multi-PI, multidisciplinary collaborations.

    ·         Supports translational studies associated with an ongoing or completed clinical trial that can lead to a future clinical trial or clinical application in cancer research relevant to Service members, their families, and other military beneficiaries.

    ·         Not intended to support high throughput screenings, sequencing, etc.

    ·         Must address at least one of the FY19 PRCRP Topic Areas.

    ·         Must address at least one of the FY19 PRCRP Military Relevance Focus Areas.

    ·         Preliminary data are required.

    ·         Clinical Trials are allowed.

    ·       Maximum funding for the entire period of performance is $1,500,000 for direct costs (plus indirect costs).

    ·       Maximum period of performance is 4 years.

     

    A pre-application (letter of intent or pre-proposal) is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

     

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the PRCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 21 Feb 2019 10:34 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $14 million (M) to the Department of Defense Lung Cancer Research Program (LCRP) to support innovative, high-impact lung cancer research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency (DHA) J9, Research and Development Directorate, manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    The LCRP is providing the information in this pre-announcement to allow investigators time to plan and develop applications.  FY19 LCRP Program Announcements and General Application Instructions for the following award mechanisms are anticipated to be posted on Grants.gov in March 2019.  Pre-application and application deadlines will be available when the Program Announcements are released.  This pre-announcement should not be construed as an obligation by the government.

    Applications submitted to the FY19 LCRP must address at least one of the nine Areas of Emphasis listed below:

    • Identify innovative strategies for the screening and early detection of lung cancer.
    • Understand the molecular mechanisms of initiation and progression to clinically significant lung cancer.
    • Identify innovative strategies for prevention of the occurrence of lung cancer.
    • Identify innovative strategies for the treatment of lung cancer.
    • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer.
    • Develop or optimize predictive markers to assist with therapeutic decision-making.
    • Understand mechanisms of resistance to treatment (primary and secondary).
    • Understand contributors to lung cancer development other than tobacco.
    • Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management).

    Military Relevance:  The LCRP seeks to support research that is relevant to the healthcare needs of military Service members, Veterans, and their families.  Military relevance will be considered in determining relevance to the mission of the DHP and FY19 LCRP during programmatic review Investigators are strongly encouraged to consider the following characteristics as examples of how a project may demonstrate military relevance:

    • Use of military or Veteran populations, biospecimens, data/databases, or programs in the proposed research
    • Collaboration with Department of Defense or Department of Veterans Affairs (VA) investigators
    • Involvement of military consultants (Army, Air Force) or specialty leaders (Navy, Marine Corps) to the Surgeons General in a relevant specialty area
    • Description of how the knowledge, information, products, or technologies gained from the proposed research could be implemented in a dual-use capacity to address a military need that also benefits the civilian population
    • Explanation of how the project addresses an aspect of lung cancer that has direct relevance to military Service members, Veterans, or other military health system beneficiaries, including environmental exposures other than tobacco

    https://cdmrp.army.mil/pubs/press/2019/19lcrppreann

    Concept Award

    • Investigators at all academic levels
    • Supports highly innovative, untested, potentially groundbreaking concepts in lung cancer.
    • Emphasis on innovation.
    • Clinical trials not allowed.
    • Preliminary data discouraged.
    • Military relevance strongly encouraged.
    • Maximum funding of $100,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 1 year.

    Career Development Award

    • Principal Investigator:  Independent investigators at the level of Assistant Professor, Instructor, or equivalent; must be within 5 years of first faculty appointment
    • Supports early-career, independent researchers to conduct research under mentorship of an experienced lung cancer researcher.
    • Clinical trials not allowed.
    • Preliminary data not required.
    • Military relevance strongly encouraged. Mentor:  At or above the level of Associate Professor (or equivalent); have a proven publication and funding record in lung cancer research
    • Maximum funding of $250,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 2 years.

    Idea Development Award

    • Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent); or
    • New Investigators:  Investigators that meet the following criteria at the application submission deadline date:
    • Have not previously received a LCRP Idea Development Award or Early Investigator Synergistic Idea Award
    • Are within 10 years of first faculty appointment (or equivalent)
    • Supports new ideas in the early stages of development representing innovative, high-risk/high-gain research.
    • Emphasis on innovation and impact.
    • New Investigator category supports applicants early in their faculty appointments or in the process of developing independent research careers.
    • Clinical trials not allowed.
    • Preliminary data required, but may be from outside of lung cancer.
    • Military relevance strongly encouraged.
    • Maximum funding of $350,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 2 years.

    Investigator-Initiated Translational Research Award

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports translational research that will develop promising ideas in lung cancer into clinical applications.  Translational research may be defined as an integration of basic science and clinical observations.
    • This mechanism is intended to fund a broad range of translational studies including, but not limited to, the following:
      • Studies advancing/translating in vitro and/or animal studies to applications with human samples/cohorts
      • Late-stage preclinical work leading to/preparing for a clinical trial, e.g., Investigational New Drug submission
      • Correlative studies that are associated with an ongoing or completed clinical trial and projects that develop endpoints for clinical trials
    • Preliminary data required, but may be from outside of lung cancer.
    • Military relevance strongly encouraged.
    • Maximum funding of $400,000 in direct costs (plus indirect costs).
    • Period of performance should not exceed 2 years.

    Translational Research Partnership Award

    • Investigators at or above the level of Assistant Professor (or equivalent)
    • Supports partnerships between clinicians and research scientists that accelerate ideas in lung cancer into clinical applications.
      • One partner is strongly encouraged to be from either a Military Treatment Facility or a VA medical center.
    • Non-Traditional Partnerships are encouraged.
    • Small-scale clinical trials allowed.
    • Preliminary data required, but may be from outside of lung cancer.
    • Military relevance strongly encouraged.
    • Maximum combined funding of $900,000 for direct costs (plus indirect costs).
    • Maximum period of performance is 3 years.

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism will also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    Submission deadlines are not available until the Program Announcements are released.  For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the LCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Public Affairs
    301-619-9783
    usarmy.detrick.medcom-cdmrp.mbx.cdmrp-public-affairs@mail.mil


  • 20 Feb 2019 10:01 AM | Hawk Tran (Administrator)

    The FY19 Defense Appropriation provides $6 million (M) to the Department of Defense Tuberous Sclerosis Complex Research Program (TSCRP) to support innovative, high-impact TSC research.  As directed by the Office of the Assistant Secretary of Defense for Health Affairs, the Defense Health Agency, J9 Research and Development Directorate manages the Defense Health Program (DHP) Research, Development, Test, and Evaluation (RDT&E) appropriation.  The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Materiel Command (USAMRMC).

    FY19 TSCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website. 

    Focus Areas:  The goal of the FY19 TSCRP is to fund exploratory, pioneering, and transformative science that promotes discoveries in tuberous sclerosis complex (TSC), from mechanistic insights to clinical application, by supporting new ideas and investigators for the benefit of Service members, their beneficiaries, and the American public.  Within this context, the FY19 TSCRP encourages applications that address the critical needs of the TSC community in one or more of the following FY19 Focus Areas:

    • Eradicating tumors associated with TSC and TSC-associated lymphangioleiomyomatosis (LAM), including gaining a deeper mechanistic understanding of TSC signaling pathways
    • Preventing epilepsy, improving treatment, and mitigating comorbidities associated with TSC-related seizures
    • Understanding the features of TSC-Associated Neuropsychiatric Disorders (TAND) and reducing their impact through pharmacological or nonpharmacological interventions
    • Advancing clinical trial readiness through development of biomarkers, clinical endpoints, clinical pharmacokinetic/pharmacodynamic (PK/PD), patient selection and sample size determination, novel drug delivery, and treatment optimization

    https://cdmrp.army.mil/funding/tscrp

    Exploration – Hypothesis Development Award – Letter of Intent due April 18, 2019

    • Investigators at all academic levels (or equivalent), including postdoctoral fellows
    • Supports the initial exploration of innovative, high-risk, high gain, and potentially groundbreaking concepts in the TSC research field.
    • Projects involving human subjects or human biological substances must be exempt under 32 CFR 219.101(b)(4) or eligible for expedited review under 32 CFR 219.110 or 21 CFR 56.110.
    • Preliminary data are not required.
    • Clinical trials not allowed.
    • The maximum allowable funding for the entire period of performance is $150,000 in direct costs.
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
    • Maximum period of performance is year

    Idea Development Award – Letter of Intent due April 18, 2019

    Established Investigators:  Independent investigators at or above the level of Assistant Professor (or equivalent);

    Or New Investigators:  Independent investigator at or below the level of Assistant Professor (or equivalent); or Established independent investigator in an area other than TSC at or above the level of Assistant Professor seeking to transition to a career in TSC.

    • Supports ideas that have the potential to yield high-impact findings and new avenues of investigation.
    • Preliminary data are expected.
    • Clinical trials not allowed.
    • New Investigator Option supports the continued development of promising independent investigators that are early in their faculty appointments and/or the transition of established investigators from other research fields into a career in TSC research.
    • Applications from New Investigators and Established Investigators will be peer and programmatically reviewed separately
    • The maximum allowable funding for the entire period of performance is $450,000 for direct costs.
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
    • Maximum period of performance is 3 years

    Clinical Translational Research Award – Letter of Intent due April 18, 2019

    • Independent investigators at or above the level of Assistant Professor (or equivalent)
    • Supports studies that will move promising, well-founded preclinical and/or clinical research findings closer to clinical application, including, diagnosis, prognosis, or treatment of TSC.
    • Studies advancing clinical trial readiness through development of biomarkers, clinical endpoints, and validation of PK/PD are of particular interest.
    • Preference will be given to studies that involve human samples, patients, or leverage existing clinical data and/or ongoing clinical studies. 
    • Preclinical studies may be appropriate but must include a clinical component.
    • Applications may include a small, pilot clinical trial intended to inform the next step in the continuum of translational research.
    • Projects that are exploratory and/or strictly animal research will not be considered for funding.
    • Preliminary data required.
    • The maximum allowable funding for the entire period of performance is $600,000 in direct costs.
    • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement.
    • Maximum period of performance is 3 years

    A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline.  All applications must conform to the final Program Announcements and General Application Instructions available for electronic downloading from the Grants.gov website.  The application package containing the required forms for each award mechanism isl also be found on Grants.gov.  A listing of all CDMRP and other USAMRMC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

    For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org.  For more information about the TSCRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

    Point of Contact:

    CDMRP Help Desk
    301-682-5507
    help@eBrap.org


  • 12 Feb 2019 1:27 PM | Hawk Tran (Administrator)

    It's that time of the year again for you to prepare for the NPPO Annual Report to Congress. Are you ready? Here's the original message from NPPO and also their attached worksheet. Good Luck!

    ---

    We will be holding several training sessions highlighting errors to avoid in the Annual Report.  We found the NPCs with the most errors last year did not attend the training, so please plan to attend one of the sessions.  We will hold them over two weeks, one am, one mid-day and one late afternoon.  June 1st is on a Saturday this year, so the deadline will be extended until June 3, 2019.  Early submissions are greatly appreciated.

    Attached please find the 2018 NPC Annual Report Template.  Please submit this form and the other required documents by email to vhaconppo@va.gov  by June 3, 2019.  Our timeline to submit this is mid-August, so we really need your report by June 3, 2019.  Your cooperation in carefully reading the following submission instructions will be greatly appreciated:

    1. The subject line of the submission email should be titled: “Name of your city, state – NPC Annual Report for 2018.”
    1. The documents attached to the email should be:
    1. NPC Annual Report Form – please title the document as “Name of your city, state – NPC Annual Report for 2018”
    2. Form 990 – please title the document as “Name of your city, state – Form 990 for 2018”
    3. Audited financial statements – please title the document as “Name of your city, state – Audited Financials for 2018”
    4. Audit Management Letter (letter from auditors, if any) – please title the document as “Name of your city, state – Audit Management Letter (from Auditors) for 2018”

         Please do not send us copies of any letters that you have written to your auditors. 

         We only want copies of letters that your auditors have written to you.  Also, please

         submit files that are not password protected.

    Please keep in mind that your NPC must have an audit done by an independent outside auditor if your annual revenues are $500,000 or more.  If your NPC’s revenues are between $100,000 and $500,000 for the year, then an audit by an independent outside auditor is required only every three years.  Those NPCs with revenues less than $100,000 a year do not need to have audits by independent outside auditors.

    Common errors to be avoided are:

    1. Not labeling your documents as specified above.
    2. Total revenues and total expenses amounts shown on Tab 4 do not agree exactly with the amounts for revenues and expenses shown on page 1 of the Form 990.
    3. The net assets amount shown on Tab 6 does not agree with the net assets amount shown on page 1 of the Form 990.
    4. The amount of government funding received on Tab 4 should equal or exceed the total of the amount entered on Tab 7 for governmental funding sources greater than $25,000.
    5. The amount of non-governmental funding received should equal or exceed the total of the amount entered on Tab 8 for non-governmental funding sources greater than $25,000.
    6. Identifying non-governmental funding sources as being from universities when in fact they are from Federal sources.  Please identify the Federal sources and show the amounts on Tab 7 for governmental funding sources greater than $25,000.
    7. Not listing payments to employees greater than $50,000 on Tab 9.  Please de-identify the employees listed using an employee number or other number.
    8. Not listing at least three accomplishments for your NPC on Tab 10.  Please keep your “accomplishments” succinct, 20 words or less.
    9. Not showing any payroll taxes paid on Tab 5, Line 10.
    • 10.   Not listing Management and General expenses on Tab 5, Column (C).
    • 11.   Not filing the Single Audit Reports along with the audited financial statements if a Uniform Guidance audit is required.
    • 12.   Filing letters you have written to your auditors.  We are only interested in having copies of letters from your auditors back to you regarding audit findings, recommendations, deficiencies, and material weaknesses, if any.
    • 13.   Breaking up a report into more than one file.  We must have one file for each report.
    • 14.   Submitting password protected files.  We must be able to open, read, and, if convenient for us, be able to print the documents you are submitting.

                                                                               

    If you have any questions about how to properly complete the 2018 NPC Annual Report, please contact Allan Krehbiel at 301-569-3847 or allan.krehbiel@va.gov.

    Thank you in advance for submitting your 2018 NPC Annual Report by June 3.  Your cooperation in making a timely filing will be greatly appreciated and is necessary to meet the deadlines set by the Secretary and the U.S. Congress.

    2018 NPC Annual Report Template - Rev. 1-02-18.xls


1717 K ST NW Suite 900

Washington, DC 20006

P: 301-656-5005  |  admin@navref.org

Powered by Wild Apricot Membership Software